An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment
Phase of Trial: Phase IV
Latest Information Update: 28 May 2018
At a glance
- Drugs Pasireotide (Primary)
- Indications Carcinoid tumour; Meningioma; Neuroendocrine tumours; Pituitary cancer; Prostate cancer; Uveal melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 28 Mar 2018 Planned primary completion date changed from 12 Jun 2023 to 9 Jun 2023.
- 01 Mar 2018 Planned End Date changed from 1 Jul 2024 to 12 Jun 2023.
- 01 Mar 2018 Planned primary completion date changed from 1 Jul 2024 to 12 Jun 2023.